MiNK Therapeutics, Inc. (INKT) NASDAQ
9.74
-0.54(-5.25%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
9.74
-0.54(-5.25%)
Currency In USD
Address
149 Fifth Avenue
New York City, NY 10010
United States of America (the)
Phone
212 994 8250
Website
Sector
Healthcare
Industry
Biotechnology
Employees
23
First IPO Date
October 15, 2021
| Name | Title | Pay | Year Born |
| Jennifer S. Buell | President, Chief Executive Officer & Director | 453,686 | 1975 |
| Christine Klaskin | Treasurer and Principal Financial & Accounting Officer | 29,822 | 1966 |
| Garo H. Armen | Executive Chairman | 0 | 1953 |
| Eleni Chantzoura | Director & Head of Discovery | 0 | N/A |
| Terese C. Hammond | Head of Inflammatory & Pulmonary Diseases | 0 | N/A |
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.